A5050488112- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Synthesis and Biological Evaluation
- Viral Infectious Diseases and Gene Expression in Insects
- Biosimilars and Bioanalytical Methods
- T-cell and B-cell Immunology
- Virus-based gene therapy research
- CRISPR and Genetic Engineering
- Nanowire Synthesis and Applications
Cancer Center Amsterdam
2021-2024
Amsterdam University Medical Centers
2020-2024
Amsterdam UMC Location Vrije Universiteit Amsterdam
2021-2023
Vrije Universiteit Amsterdam
2020-2023
Abstract Purpose: The microenvironment of multiple myeloma (MM) can critically impair therapy outcome, including immunotherapies. In this context, we have earlier demonstrated that bone marrow mesenchymal stromal cells (BMMSC) protect MM against the lytic machinery MM-reactive cytotoxic T (CTL) and daratumumab-redirected natural killer (NK) through upregulation antiapoptotic proteins Survivin Mcl-1 in cells. Here, investigated significance mode immune escape on engineered to express chimeric...
The success of B-cell maturation antigen (BCMA)-specific chimeric receptor (CAR) T cells illustrates the potential this novel therapy for multiple myeloma. Nonetheless, broadening CAR T-cell beyond BCMA requires inventive strategies as there are only a few myeloma- or plasma cell-specific target antigens. We investigated feasibility achieving myeloma specificity by dual-split CD38/CD138 targeting, whereby stimulatory and costimulatory signals activation split into two separate (sCAR) CARs...
The past decades have illustrated the power of T-cell engineering in development new and successful cell therapies, such as chimeric antigen receptor (CAR) T-cells. Despite clinical success hematological malignancies, it also becomes increasingly clear that additional will be required to improve efficacy safety expand application solid tumors. Engineering is most often achieved by viral delivery transgenes, however, vector capacity limitations make efficient reproducible generation multi...
<p>Supplemental Figures</p>
<div>Abstract<p>Purpose: The success of BCMA-specific chimeric antigen receptor (CAR) T-cells illustrates the potential this novel therapy for multiple myeloma (MM). Nonetheless, broadening CAR T-cell beyond BCMA requires inventive strategies as there are only a few MM- or plasma cell-specific target antigens. We investigated feasibility achieving MM specificity by dual-split CD38/CD138 targeting, whereby stimulatory and costimulatory signals activation split into two separate...
<p>Supplemental Figures</p>
<p>Table providing information on scFv sequences CARs. Figures data CAR T cell phenotype, BMMSC survival, target antigen expression, cytotoxic mediator measurements, Survivin and Mcl-1 expression in MM cells, effector vivo efficacy of BCMA-CAR cells.</p>
<p>Table providing information on scFv sequences CARs. Figures data CAR T cell phenotype, BMMSC survival, target antigen expression, cytotoxic mediator measurements, Survivin and Mcl-1 expression in MM cells, effector vivo efficacy of BCMA-CAR cells.</p>
<div>AbstractPurpose:<p>The microenvironment of multiple myeloma (MM) can critically impair therapy outcome, including immunotherapies. In this context, we have earlier demonstrated that bone marrow mesenchymal stromal cells (BMMSC) protect MM against the lytic machinery MM-reactive cytotoxic T (CTL) and daratumumab-redirected natural killer (NK) through upregulation antiapoptotic proteins Survivin Mcl-1 in cells. Here, investigated significance mode immune escape on engineered...
<div>AbstractPurpose:<p>The microenvironment of multiple myeloma (MM) can critically impair therapy outcome, including immunotherapies. In this context, we have earlier demonstrated that bone marrow mesenchymal stromal cells (BMMSC) protect MM against the lytic machinery MM-reactive cytotoxic T (CTL) and daratumumab-redirected natural killer (NK) through upregulation antiapoptotic proteins Survivin Mcl-1 in cells. Here, investigated significance mode immune escape on engineered...
<p>Supplemental Figures</p>
<p>Supplemental Figures</p>
<div>AbstractPurpose:<p>The success of B-cell maturation antigen (BCMA)-specific chimeric receptor (CAR) T cells illustrates the potential this novel therapy for multiple myeloma. Nonetheless, broadening CAR T-cell beyond BCMA requires inventive strategies as there are only a few myeloma– or plasma cell–specific target antigens. We investigated feasibility achieving myeloma specificity by dual-split CD38/CD138 targeting, whereby stimulatory and costimulatory signals activation...
<div>Abstract<p>Purpose: The success of BCMA-specific chimeric antigen receptor (CAR) T-cells illustrates the potential this novel therapy for multiple myeloma (MM). Nonetheless, broadening CAR T-cell beyond BCMA requires inventive strategies as there are only a few MM- or plasma cell-specific target antigens. We investigated feasibility achieving MM specificity by dual-split CD38/CD138 targeting, whereby stimulatory and costimulatory signals activation split into two separate...